BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) and Cipla, Ltd., a leading Indian pharmaceutical company located in Mumbai, India, today announced the signing of an exclusive drug development and supply agreement for an oral ANDA drug product for the prevention of organ transplant rejection. According to 2006 IMS data, this drug product has a total market size of approximately $750 million for all indications.
